Viruses On The Verge Of Joining The War On Cancer
This article was originally published in Start Up
Executive Summary
With new approaches in development that add or subtract genetic material to viruses, or arm them with immune-boosting proteins, oncolytic viruses may become the next modality for treating cancer. Several smaller companies and their backers – as well as those who have yet to invest in the space – eagerly await results from Amgen’s Phase III program OncoVex.
You may also be interested in...
UniQure’s Glybera Is First Gene Therapy Okayed In Western Europe
UniQure’s Glybera (alipogene tiparvovec) has become the first gene therapy to be approved for commercialization in the 27-nation European Union, marking a major step towards making such medicines available for treating rare diseases that have a high unmet medical need.
Oncologists Audition Yervoy And Zelboraf For First-line Roles, With New Combos In Near Sight
Cooperative group plans trial testing Yervoy vs. Zelboraf in first-line metastatic melanoma to help settle the issue of which therapy should come first in BRAF-mutation positive patients. New therapies on the way promise to further complicate decision-making.
Natural Products: Back In Vogue?
Several small biotechs are heading back to nature, spotting promising drug targets in exotic plants, sea creatures, and venomous animals, even as Big Pharma and venture capital remain skeptical of the approach.
Need a specific report? 1000+ reports available
Buy Reports